Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants With Nonsegmental Vitiligo

NCT07108283 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT07108283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07108283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants With Nonsegmental Vitiligo
Lead sponsor
Takeda
Phase
Phase 2
Overall status
Recruiting
Start date
November 3, 2025
Completion date
November 9, 2027
Enrollment
200 (estimated)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

nonsegmental vitiligo